- Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis
- Second quarter diluted earnings per share were $1.03, an increase of 33.8%; adjusted1 diluted earnings per share were $2.07, consistent with the prior year period
- Company updates full-year 2026 financial guidance
WARSAW, Ind., Aug. 5, 2026 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and (SIX: ZBH) today reported financial results for the quarter ended June 30, 2026. The Company reported second quarter net sales of $2.177 billion, an increase of 4.8% over the prior year period, an increase of 4.7% on a constant currency1 basis and an increase of 4.0% on an organic constant currency1 basis. Net earnings for the second quarter were $198.3 million, or $399.6 million on an adjusted1 basis.
Diluted earnings per share were $1.03 for the second quarter, an increase of 33.8%, and adjusted1 diluted earnings per share were $2.07, consistent with the prior year period. Zimmer Biomet generated $447.9 million in operating cash flow and $308.3 million of free cash flow1 in the second quarter.
| 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. |
“We delivered strong second quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted EPS guidance for the year. Importantly, we continue to advance our strategic priorities and remain confident our efforts will strengthen our business, build the boldest leader in MedTech, and better position Zimmer Biomet to deliver consistent, durable growth over the long term.”
Recent Highlights
- Announced increase to share repurchase expectations of up to $1 billion of its common stock during fiscal year 2026.
- Received U.S. FDA 510(k) clearance and completed first cases of the next generation ROSA® Shoulder System, the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques.
- Recognized as “Best Healthcare Robotics Solution” in 2026 MedTech Breakthrough Awards ROSA® Knee with OptimiZe™.
- Named Chintan Desai president of the company’s Asia Pacific Region to replace Sang Yi, who will depart the company on Aug. 28.
- Named to TIME’s 2026 list of America’s Best Companies, demonstrating excellence across employee satisfaction, financial results and sustainability transparency.
- Issued 2025 Sustainability Report, highlighting meaningful progress reducing the company’s environmental footprint, strengthening communities and expanding access to care.
- Zimmer Biomet Institute held its inaugural Sharpening Your Edge immersive, hands-on bioskills training experience, designed to deliver immediate, practice-ready impact to early career surgeons.
Geographic and Product Category Sales
The following sales tables provide results by geography and product category for the three and six-month periods ended June 30, 2026, as well as the percentage change compared to the prior year periods, on both a reported basis and a constant currency basis. Percentage change is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28, Inc. (“Paragon 28”).
